Investigating the role of METTL3 in aggressive chronic lymphocytic leukemia
Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia
This study is looking at how a protein called METTL3 affects aggressive chronic lymphocytic leukemia (CLL) and is testing new treatments that could help patients by targeting this protein.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10880367 on NIH RePORTER |
What this research studies
This research focuses on understanding how the METTL3 protein contributes to the development and progression of aggressive chronic lymphocytic leukemia (CLL). By analyzing the RNA and protein changes in CLL cells, the researchers aim to uncover the mechanisms by which METTL3 influences cancer behavior. The study also explores the potential of small molecule inhibitors targeting METTL3 as a new treatment option for patients with CLL. If successful, this research could lead to more effective therapies tailored to the biology of aggressive CLL.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive chronic lymphocytic leukemia who may benefit from novel treatment approaches.
Not a fit: Patients with indolent forms of chronic lymphocytic leukemia or those not diagnosed with CLL may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new targeted therapies for patients with aggressive chronic lymphocytic leukemia.
How similar studies have performed: Other research has shown promising results with similar approaches targeting RNA splicing in hematological malignancies, indicating potential for success in this area.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Wang, Lili — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Lili
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.